###### Key messages

What is the key question?
=========================

-   To assess the safety and feasibility of the objective measurement of compliance during oral appliance (OA) therapy for sleep-disordered breathing (SDB) using a microsensor thermometer embedded in the OA.

What is the bottom line?
========================

-   Although OA therapy is reported to be efficacious for the treatment of SDB, data on compliance remain limited to self-report.

Why read on?
============

-   The objective measurement of OA compliance allows for the calculation of the mean disease alleviation, defined as a combined function of efficacy and compliance, being a measure of the overall therapeutic effectiveness, and will become imperative in the evaluation of OA therapy success rates in the treatment of SDB.

Introduction {#s1}
============

The prevalence of sleep-disordered breathing (SDB) is remarkably high among middle-aged adults, with estimates reaching 9% for women and 24% for men.[@R1] SDB in adults spans a wide pathophysiological continuum of severity, from snoring over obstructive sleep apnoea (OSA) to obesity hypoventilation syndrome.[@R2] Epidemiological studies provide clear evidence that SDB is a strong and independent risk factor for hypertension with consequent cerebro- and cardiovascular morbidity and high mortality.[@R3; @R4; @R5] As a result, SDB has major socioeconomic consequences.[@R6]

OSA is characterised by repetitive pharyngeal collapse (apnoea) or upper airway narrowing (hypopnoea) during sleep, leading to hypoxaemia and hypercapnia, and causing sleep fragmentation that in turn leads to daytime sleepiness and increased risk of motor vehicle and occupational accidents.[@R7; @R8; @R9] OSA is defined as the occurrence of more than five apnoeas and hypopnoeas per hour of sleep, expressed as the apnoea/hypopnoea index, or apnoea/hypopnoea index (AHI). The American Academy of Sleep Medicine (AASM) considers an AHI of between five and 15 to be mild OSA, between 15 and 30 to be moderate OSA, and \>30 to be severe OSA.[@R10]

The gold standard for the treatment of OSA is continuous positive airway pressure (CPAP).[@R11] [@R12] CPAP improves systemic hypertension, and it has been demonstrated that successful CPAP treatment prolongs survival.[@R5] Because of the high efficacy of CPAP, the therapeutic effectiveness of CPAP is potentially high. Its clinical effectiveness, however, is often limited by low patient acceptance, poor tolerance and a suboptimal CPAP compliance.[@R13] [@R14] Therefore, CPAP could result in a less favourable effectiveness than required.[@R13] Accordingly, non-CPAP alternatives for the treatment of SDB have gained growing interest.[@R13] [@R15] [@R16] Oral appliance (OA) therapy is increasingly prescribed as a non-invasive first-line alternative to CPAP.[@R15] Mandibular advancement devices, which are worn intraorally at night to advance the mandible, are currently the most common class of OAs used to treat SDB.[@R16; @R17; @R18; @R19] The efficacy of OA therapy has been demonstrated in randomised controlled clinical trials, and there is emerging evidence on its beneficial cardiovascular effects.[@R15] [@R20] [@R21] OA therapy is indicated in subjects who do not tolerate or comply with CPAP, and it may be a first-line treatment in snorers and patients with mild to moderate OSA.[@R15] OA therapy can also be considered as a temporary alternative for CPAP, or a rescue treatment after upper airway surgery failure.[@R7] [@R15] [@R22]

As a part of clinical routine, CPAP treatment incorporates a well established objective measurement of CPAP use.[@R14] [@R23] [@R24] To date, objective measurement of compliance during OA therapy for SDB remains restrained.[@R15] [@R25] [@R26]

In this article, we describe the results of a 3-month prospective clinical trial assessing the safety and feasibility of the objective measurement of OA compliance using an embedded microsensor thermometer with on-chip integrated readout electronics.

Methods {#s2}
=======

Study design {#s2a}
------------

A structured written informed consent procedure was used. Subjects enrolled in the study were unaware that compliance with their OA was being measured objectively, and they were not paid for participation (for detailed information on the study protocol, see the online data supplement).

Measurements {#s2b}
------------

Objective measurement of OA compliance was performed using an embedded microsensor thermometer ([figure 1](#THORAXJNL20122201900F1){ref-type="fig"}). Objective compliance measurement was based on the assumption that the OA therapy was being used when the temperature measured was higher than 35°C. The microsensor was embedded in the upper right side of the OA ([figure 2](#THORAXJNL20122201900F2){ref-type="fig"}).

![The microsensor thermometer with on-chip integrated readout electronics used in this study (TheraMon, IFT Handels- und Entwicklungsgesellschaft GmbH, Handelsagentur Gschladt, Hargelsberg, Austria) has a weight of 0.40±0.01 g, a length of 13.0±0.1 mm, a width of 9.0±0.1 mm and a height of 4.3±0.1 mm. The sampling interval of the temperature recording was programmed at one measurement per 15 min with a memory capacity of approximately 100 consecutive days.](thoraxjnl-2012-201900f01){#THORAXJNL20122201900F1}

![The microsensor is sealed into the upper right side of the custom-made titratable mandibular advancement device.](thoraxjnl-2012-201900f02){#THORAXJNL20122201900F2}

Additional details regarding the OA and the OA compliance monitor can be found in the online data supplement.

Safety and feasibility endpoints {#s2c}
--------------------------------

The safety endpoint was the absence of any microsensor-related adverse effects ([box 1](#THORAXJNL20122201900BX1){ref-type="boxed-text"}). To determine these adverse effects, patients were interviewed during each follow-up evaluation about possible adverse effects, and an oral examination was performed. The OA was also examined by the dental sleep professional, including a detailed inspection of the area with the embedded microsensor. The feasibility endpoint was a successful readout of the compliance data from the microsensor. Box 1Microsensor-related adverse effects as defined for the purpose of this studyThe occurrence of oral burn injuriesOther microsensor-related lesions to the oral mucosaDetachment of the microsensor from the oral appliance

OA compliance measurements {#s2d}
--------------------------

The objective OA compliance data were expressed as objective mean rate of OA use in number of hours of OA use per day, and as percentage of days of OA use per week. Patients were considered compliant when objective OA use ≥4 h per day. According to the literature, a set of two user patterns was identified ([table 2](#THORAXJNL20122201900TB2){ref-type="table"}).[@R14] [@R24]

Self-reported OA compliance and self-reported total sleep time (TST) were assessed using a diary filled out by the patient on each day of the 3-month follow-up period during the intervals between the follow-up visits.

Adjusted compliance will be calculated as the objective mean rate of OA use divided by TST.

Polysomnographic outcome {#s2e}
------------------------

All patients underwent an attended, overnight level I polysomnography with OA 3 months after the start of OA therapy. Treatment response and treatment success were defined by a ≥50% reduction in AHI and an AHI \<5/h sleep, respectively. Therapeutic OA efficacy was defined as baseline AHI minus AHI with OA, expressed in percentage.

OA effectiveness {#s2f}
----------------

According to the 'disease alleviation concept',[@R13] objective measurement of OA compliance allows us to calculate the mean disease alleviation (MDA) (%), as a measure of therapeutic OA effectiveness. MDA is given by the product of adjusted compliance with therapeutic OA efficacy, divided by 100. The overall remaining AHI was calculated as the product of baseline AHI and (100 minus MDA)/100.

Statistics {#s2g}
----------

Data were statistically analysed using SPSS (SPSS V.17.0, SPSS Inc, Chicago, Illinois, USA). The significance level was set at 0.05. Quantitative variables were presented as mean±SD. Normality of distribution was assessed using the Kolmogorov--Smirnov test. OA treatment effects were analysed with a paired t-test if the data were normally distributed, and with the Wilcoxon signed-rank test if they were not. To compare the data on self-reported OA compliance with the objective OA use a Wilcoxon signed-rank test was performed.

Results {#s3}
=======

A group of 51 patients with an established diagnosis of SDB based on an attended, overnight level I polysomnography (age 47±10 y; BMI 26.6±4.0 kg/m^2^; men/women: 31/20; AHI 18.0±11.9/h sleep; Epworth sleepiness scale 10.8±4.7) who were undergoing OA therapy were included[@R10] [@R17] [@R27; @R28; @R29] (for details, see the online data supplement).

Safety and feasibility endpoints {#s3a}
--------------------------------

Based on history and clinical examination at both the 1-month and the 3-month follow-up visit, no microsensor-related adverse events ([box 1](#THORAXJNL20122201900BX1){ref-type="boxed-text"}) were recorded. Detailed inspection of the OAs during any follow-up evaluation did not reveal any abnormalities or changes to the area of the OA where the microsensor was embedded. No detachments have occurred.

From a feasibility perspective, no problems were encountered during the readout of the compliance data during any of the follow-up evaluations. One out of 51 microsensors had a technical defect and was lost to follow-up.

OA compliance measurements {#s3b}
--------------------------

No patients discontinued OA therapy during the 3-month follow-up period. The readout of the OA-compliance monitor data was performed at a 1-month (32±3 days) and a 3-month (95±8 days) interval. In four patients, the final readout date exceeded the 100-day storage period of the microsensor, and in four other patients compliance data were read out for the first and second months, but not obtained for the total 3-month period. Therefore, for the complete follow-up period, compliance data are available for 43 out of 51 patients ([table 1](#THORAXJNL20122201900TB1){ref-type="table"}). Over the 3 months, the objective OA use was consistently 6.7±1.3 h per day with OA being used on 91.9±10.8% of days per week (n=43) ([table 1](#THORAXJNL20122201900TB1){ref-type="table"}). Forty-two out of 45 patients (93%) had an objective mean rate of OA use that exceeded 4 h per day and were considered compliant. Overall, the self-reported TST for the whole follow-up period was 7.5±0.9 h/day. The percentages of regular and frequent users are shown in [table 2](#THORAXJNL20122201900TB2){ref-type="table"}. The percentage of regular users was consistently 84% over the 3 months (n=43).

###### 

The objective mean rate of OA use, expressed in hours per day, and the percentage of days of OA use per week for the separate months and consistent for the 3-month study period

                             objective mean rate of OA use (h/day)   Objective % days/week   n
  -------------------------- --------------------------------------- ----------------------- ----
  First month                6.8±1.4                                 93.3±11.3               43
  Second month               6.7±1.3                                 92.5±11.2               43
  Third month                6.6±1.6                                 91.8±14.5               43
  Consistent over 3 months   6.7±1.3                                 91.9±10.8               43

Data are presented as mean±SD.

OA, oral appliance.

###### 

A set of two user patterns\* was identified and calculated: percentages of regular and frequent users over the separate months and consistent for the 3-month study period

                             Regular users   \%   Frequent users   \%
  -------------------------- --------------- ---- ---------------- ----
  First month                45/50           90   45/50            90
  Second month               41/45           91   40/45            89
  Third month                36/43           84   36/43            84
  Consistent over 3 months   36/43           84   34/43            79

\*Patients were classified as 'regular users' if they completed at least 4 h of active oral appliance (OA) treatment on more than 70% of the days of the week, as defined by Kribbs *et al.*[@R14] Patients were classified as 'frequent users' when they met the more restrictive criteria introduced by Pepin *et al*: mean OA use of more than 5 days per week and more than 4 h per day.[@R24]

Statistical analysis revealed no significant differences between objective and self-reported OA compliance data in this study ([table 3](#THORAXJNL20122201900TB3){ref-type="table"}).

###### 

Median values and first and third quartiles (Ql; Q3) of objective and self-reported mean rate of OA use data as assessed during the intervals between the follow-up visits

                       Median objective compliance (h/day)   Median self-reported compliance (h/day)   p Value   N
  -------------------- ------------------------------------- ----------------------------------------- --------- ----
  First month          7.24 (6.72; 7.87)                     7.34 (6.06; 7.83)                         0.804     31
  Second+third month   7.13 (6.69; 7.66)                     7.21 (6.69; 7.76)                         0.576     31

OA, oral appliance.

Polysomnographic outcomes {#s3c}
-------------------------

For 43 of the 51 patients, polysomnography with OA was obtained ([table 4](#THORAXJNL20122201900TB4){ref-type="table"}). Overall, treatment response and treatment success occurred in 62% and 50% of patients, respectively. Mean AHI decreased from 18.4±11.5 at baseline to 7.0±6.5/h sleep with OA (p\<0.001), leading to an OA efficacy of 56.0±38.2% (n=43).

###### 

Data at baseline compared with data after OA use

  Parameter                  Baseline (mean±SD)         With OA (mean±SD)          p Value
  -------------------------- -------------------------- -------------------------- ---------
  AHI (events/h)             18.4±11.5                  7.0±6.5                    \<0.001
  ODI (events/h)             6.2±7.5                    2.8±3.0                    \<0.01
  Mean sat (%)               94.7±1.4                   95.0±1.3                   0.254
  Min sat (%)                85.1±6.8                   85.7±6.6                   0.658
  TST (uu:mm:ss)             06 : 02 : 15±1 : 29 : 52   06 : 16 : 22±1 : 31 : 40   0.600
  \% S1 in TST               8.0±4.9                    5.0±3.5                    0.001
  \% S2 in TST               49.8±10.3                  52.1±11.5                  0.287
  \% S3 in TST               21.8±8.9                   22.1±10.6                  0.865
  \% REM in TST              20.2±6.5                   20.8±6.2                   0.607
  Arousal index (events/h)   15.5±14.0                  7.6±3.4                    0.004
  ESS (/24)                  10.8±4.7                   7.8±4.8                    \<0.001
  Snoring index (0--10)      6.5±2.6                    2.4±2.3                    \<0.001
  BMI (kg/m^2^)              26.6±4.2                   26.7±4.1                   0.767

ESS, Epworth sleepiness scale; OA, oral appliance; ODI, Oxygen Desaturation Index; REM, Rapid Eye Movement; TST, total sleep time; AHI, apnoea/hypopnoea index.

OA effectiveness {#s3d}
----------------

In [figure 3](#THORAXJNL20122201900F3){ref-type="fig"}, the individual OA efficacy percentages are plotted against the individual OA compliance data expressed in percentage of days of OA use per week. Over the 3-month follow-up period, adjusted compliance (objective OA use/TST) was 91.2±10.1% (range 67.8%--100%). MDA was 51.1% and was calculated by the product of OA efficacy and adjusted compliance divided by 100 (see [figure 4](#THORAXJNL20122201900F4){ref-type="fig"}). The overall remaining AHI was 7.8±5.4/h sleep, calculated as the product of baseline AHI and (100 minus MDA)/100.

![The individual oral appliance (OA) efficacy percentages plotted against the individual OA compliance data, expressed in percentage of days of OA use per week.](thoraxjnl-2012-201900f03){#THORAXJNL20122201900F3}

![Mean disease alleviation (MDA) is equal to the surface area of the rectangle for which the length is given by the adjusted compliance (objective oral appliance (OA) use/total sleep time), and the height is given by the therapeutic efficacy (AHI baseline minus AHI with OA applied, expressed in percentage). MDA provides a measure of overall therapeutic effectiveness.](thoraxjnl-2012-201900f04){#THORAXJNL20122201900F4}

Discussion {#s4}
==========

Objective measurements of CPAP compliance with a built-in measurement of actual compliance have become a routine part of daily clinical practice.[@R12] [@R23] By contrast, OA therapy lacks the possibility to record objective daily use, as compliance data remain limited to self-report.[@R15] In the 2005 AASM practice parameter report, Kushida *et al* claim that the development of similar capabilities to monitor OA compliance in an objective fashion are required for both research and clinical purposes.[@R15] As in the early years of CPAP,[@R23] there is a strong interest in this objective compliance measurement. The present study reports in-depth on the safety and feasibility of objective compliance monitoring during OA therapy. This objective measurement of OA compliance allowed us to establish the MDA as a measure of therapeutic effectiveness.

In our prospective study, no adverse effects were noted related to the compliance monitoring using an active microsensor thermometer ([box 1](#THORAXJNL20122201900BX1){ref-type="boxed-text"}), illustrating the safety of this device. Only 1 out of 51 microsensors had a technical defect. During 3 months of OA therapy, it was feasible to obtain data on objectively measured compliance ([table 1](#THORAXJNL20122201900TB1){ref-type="table"}). Objective OA use was high, with patients using the therapy on average 6.7±1.3 h per day over the 3-month follow-up period consistently, while the 3-month regular users' rate was 84% ([table 2](#THORAXJNL20122201900TB2){ref-type="table"}). These high OA use rates clearly illustrate that compliance probably is not a major limitation in the use of OAs for the treatment of SDB.[@R31]

Two previous papers have been published in the literature that are relevant to this study. Lowe *et al* were the first to report on the direct intraoral recording of OA compliance during sleep over a 2-week time span in eight OSA patients.[@R25] Their compliance monitor was composed of a ceramic thick-film hybrid with a memory system and a temperature sensor.[@R25] Objective OA use values of 6.9 h/day were recorded, and thus, the study showed comparable high compliance data during OA therapy. Nevertheless, several problems were reported with the compliance monitors that were used, including heat intolerance of the electronic components and high energy consumption over longer sampling periods.[@R25]

Inoko *et al* reported on the assessment of the cytotoxicity of a temperature data logger in six OSA patients during 1 month.[@R26] In this study, the surface of the temperature data logger was coated with a temporary sealing material to prevent contact with oral mucosa.[@R26] Another limitation of this specific study was the dimensions of the temperature data logger, which had a diameter of 17.4 mm, a thickness of 5.9 mm, and a weight of about 3.3 g[@R26] as compared with the microsensor thermometer used in our study having a weight of only 0.4 g and a length, width and height of 13, 9 and 4.3 mm, respectively ([figure 1](#THORAXJNL20122201900F1){ref-type="fig"}). It is possible that the technical problems limiting the use of compliance monitors in both these studies[@R25] [@R26] impeded the availability of objective measurement of OA compliance in the field of sleep medicine to date.

To the authors' best knowledge, our study is the first to report the safety and feasibility of objective compliance monitoring during OA therapy in a larger group of SDB patients over a 3-month period. Another important result of this study is the establishment of the MDA calculation. The availability of an objective measurement of compliance allowed us to introduce this calculation into the field of OA therapy as a measure of the overall therapeutic effectiveness, given by the product of adjusted compliance and OA efficacy, divided by 100 and expressed in percentage. MDA was 51.1% in the reported study ([figure 4](#THORAXJNL20122201900F4){ref-type="fig"}). These figures on therapeutic effectiveness support the hypothesis that higher compliance with mandibular advancement device type of OA therapy translates into a similar adjusted effectiveness as compared with CPAP.[@R32] Although mandibular advancement device treatment is inferior to CPAP in reducing the AHI, its MDA values might be comparable with those of CPAP because of the higher compliance with OA therapy.[@R32]

Taking into account the fact that even the most effective medical device is only effective when it is used, the authors believe that MDA calculation is of high interest because there is a clear need for well-defined criteria to compare the effects of CPAP therapy and non-CPAP treatment options.[@R33] In the past, the absence of a safe and reliable method for objective measurement of OA compliance prevented calculation of MDA for OA therapy. The results of this study provide evidence to overcome this limitation. With CPAP, about 50% adjusted effectiveness is observed when accounting for sleep time, its actual effect and use.[@R13] [@R33] In a recent paper, Ravesloot *et al* provided evidence that the effectiveness of suboptimal use of CPAP therapy could indeed be comparable with the subtherapeutic effect of a given surgical treatment.[@R33] In our study, the overall therapeutic effectiveness during OA therapy was 51.1%, combining a high compliance with a suboptimal efficacy ([figure 4](#THORAXJNL20122201900F4){ref-type="fig"}). Moreover, in the reported study, no patients discontinued OA therapy during the 3-month follow-up period, whereas approximately 20%--40% of patients will discontinue CPAP after 3 months.[@R34]

We believe the use of a titratable custom-made mandibular advancement device is another strength of our study, as this type of OA is currently recommended.[@R16] [@R17] [@R30] [@R32] [@R35] It has been reported that both comfort and efficacy might turn out to be higher with such titratable custom-made appliances, presumably leading to an improvement in compliance and effectiveness.[@R35]

The present study has its limitations and shortcomings. First, only a relatively small number of patients were included, and the follow-up period was relatively short. Further prospective evaluation with a larger number of patients and longer follow-up periods are required to confirm these first results. The second limitation was that the reported study, as a safety and feasibility trial, had no control group. However, we believe this bias was minimal because patients were unaware that their OA compliance was being measured objectively. As this was a clinical research trial, differences may occur in a daily clinical practice with a stricter follow-up schedule. There is a lower tendency for drop-out in a clinical study as compared with daily clinical practice. Another bias might have been introduced by the fact that the study group mainly consisted of patients with mild to moderate OSA. It is well known that mandibular advancement devices are more successful in the treatment of mild to moderate OSA than severe OSA.[@R16] [@R25] Moreover, patients suitable for and willing to start OA therapy were preselected after clinical dental and ENT examination.

Despite its limitations, we expect that this study will be able to serve as a key step forward in the development of future guidelines concerning both clinical practice and research projects. The microsensor thermometer used in this study ([figure 1](#THORAXJNL20122201900F1){ref-type="fig"}) has proven to be reliable within the 3-month follow-up period. Extended follow-up is needed to provide additional information on the long-term safety and feasibility of this chip, including the life time and battery life of the chip.

The authors believe that the results of this study have important implications for future clinical trials evaluating OA therapies for patients with SDB as an objective measurement of OA use, and that OA compliance will become imperative in the evaluation of OA therapy success rates. In addition, as with CPAP treatment, a compliance-based coverage of OA therapy might be adopted by healthcare programs and insurance companies.[@R36]

Conclusions {#s5}
===========

The removable nature of an OA warrants objective assessment of its effective use and compliance in the treatment of SDB. Although there is a strong interest in this type of assessment, objective measurement has been restrained to date. Our findings suggest that objective measurement of OA compliance during SDB treatment is safe and feasible.

Consistently over the 3-month follow-up period, the rate of regular OA users was 82% with an average objective OA use of 6.7±1.3 h per day. Compared with CPAP compliance that is often poor, the high levels of compliance during OA therapy in this study are favourable. This relatively high compliance will favourably influence the MDA, defined as a combined function of efficacy and compliance, being a measure of the overall therapeutic effectiveness of this specific therapeutic option as compared with other treatment modalities for SDB.[@R13] In the reported study, the MDA was calculated as 51.1%, which is comparable with the 50% adjusted CPAP effectiveness.[@R13] These results fit the hypothesis that mandibular advancement device treatment, despite being inferior to CPAP in reducing the AHI, might translate into a similar adjusted AHI and effectiveness because of a higher compliance.[@R32]

Based on the results of this study, it is recommended that actual OA use should be objectively recorded in all SDB patients undergoing OA therapy, and that the use of an objective instrument to measure OA compliance should be implemented in future studies. Further prospective studies with larger numbers of patients and longer follow-up periods are required to confirm our first results and to assess the evolution of OA compliance patterns over time.

Supplementary Material
======================

###### Web appendix

The TheraMon microsensor thermometers and readout equipment used in this study were provided free of charge by IFT Handels- und Entwicklungsgesellschaft GmbH, Handelsagentur Gschladt, Hargelsberg, Austria. The TheraMon microsensor thermometers were sealed in the Respident Butterfly MRA oral appliances by the Respident dental laboratory, Schoten, Belgium, free of charge. We are grateful to both for their support. The supporting companies had no role in study design, data collection, data analysis, data interpretation or writing of the report.
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